Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer

Cited by (1,000)

Items 101–200 of 1,000

1. Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)
   Powell, Chelsea E., Gao, Yang, Tan, Li, Donovan, Katherine A., Nowak, Radosław P., Loehr, Amanda, Bahcall, Magda, Fischer, Eric S., Jänne, Pasi A., George, Rani E. et al. · 2018 · Journal of Medicinal Chemistry
2. Small molecule inhibitors targeting the cancers
   Guihong Liu, Tao Chen, Xin Zhang, Xuelei Ma, Shi H · 2022 · MedComm
3. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
   Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M.A., Michels, S., Nogova, L., Fassunke, J. et al. · 2018 · Annals of Oncology
4. Advances in molecular pathology and therapy of non-small cell lung cancer
   Huang, Qing, Li, Yuanxiang, Huang, Yingdan, Wu, Jingyi, Bao, Wendai, Xue, Chang, Li, Xiaoyu, Dong, Shuang, Dong, Zhiqiang, Hu, Sheng · 2025 · Signal Transduction and Targeted Therapy
5. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer
   Matthew P. Smeltzer, Murry W. Wynes, Sylvie Lantuéjoul, Ross Andrew Soo, Suresh S. Ramalingam, Marileila Varella‐Garcia, Meghan M. Taylor, K. Richeimer, K. Wood, Kristen E. Howell et al. · 2020 · Journal of Thoracic Oncology
6. Cells of origin of lung cancers: lessons from mouse studies
   Giustina Ferone, Myung Chang Lee, Julien Sage, Anton J. M. Berns · 2020 · Genes & Development
7. ALK-positive lung cancer: a moving target
   Jaime Laurel Schneider, Jessica J. Lin, Alice Tsang Shaw · 2023 · Nature Cancer
8. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)
   Sehhoon Park, Tae Min Kim, Ji‐Youn Han, Gyeong‐Won Lee, Byoung Yong Shim, Yun‐Gyoo Lee, Sang‐We Kim, Il Hwan Kim, Suee Lee, Yu Jung Kim et al. · 2023 · Journal of Clinical Oncology
9. Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
   Leora Horn, Jeffrey R. Infante, Karen L. Reckamp, George R. Blumenschein, Ticiana A.B. Leal, Saiama Naheed Waqar, Barbara Jennifer Gitlitz, Rachel E. Sanborn, Jennifer G. Whisenant, Liping Du et al. · 2018 · Clinical Cancer Research
10. Crizotinib in MET -Deregulated or ROS1 -Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
    Lorenza Maria Landi, Rita Chiari, Marcello Tiseo, Federica D’Incà, Claudio Dazzi, Antonio Chella, Angelo Delmonte, Laura Bonanno, Diana Giannarelli, Diego Luigi Cortinovis et al. · 2019 · Clinical Cancer Research
11. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
    Joshua Saul Davis, David Ferreira, Emma K. Paige, Craig A. Gedye, Michael Boyle · 2020 · Clinical Microbiology Reviews
12. Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
    Frank Griesinger, Giuseppe Curigliano, Michael Thomas, Vivek Subbiah, Christina S. Baik, Daniel S.W. Tan, Daniel Lee, D Misch, Elena Garralda, D.-W. Kim et al. · 2022 · Annals of Oncology
13. Management of Brain Metastases in Non–Small-Cell Lung Cancer
    Vinicius Ernani, Thomas E. Stinchcombe · 2019 · Journal of Oncology Practice
14. Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity
    Yu, Yingjie, Liu, Aiyao, Dhawan, Gagan, Mei, Haibo, Zhang, Wei, Izawa, Kunisuke, Soloshonok, Vadim A., Han, Jianlin · 2021 · Chinese Chemical Letters
15. An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access
    Natasha B. Leighl, Sharon Nirmalakumar, Doreen Anuli Ezeife, Bishal Gyawali · 2021 · American Society of Clinical Oncology Educational Book
16. Management of brain metastases according to molecular subtypes
    Riccardo Soffietti, Manmeet Singh Ahluwalia, NU Lin, Roberta Rudà · 2020 · Nature Reviews Neurology
17. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer
    Gideon Michael Blumenthal, Yuexuan Gong, Kenneth L. Kehl, Pallavi Shruti Mishra-Kalyani, Kirsten B. Goldberg, Sean Khozin, Paul Gustav Kluetz, Geoffrey R. Oxnard, Richard Pazdur · 2019 · Annals of Oncology
18. Clinical Management of Adverse Events Associated with Lorlatinib
    Todd Michael Bauer, Enriqueta Felip, Benjamin Solomon, Holger C. Thurm, Gerson Peltz, Marc D. Chioda, Alice Tsang Shaw · 2019 · The Oncologist
19. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
    Margarita Majem, Óscar Juan, Amelia Insa, Noemí Reguart, José Manuel Trigo, Enric Carcereny, Rosario García‐Campelo, Yolanda García García, María Guirado, Mariano Provencio · 2018 · Clinical & Translational Oncology
20. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer
    Leora Horn, Jennifer G. Whisenant, Heather A. Wakelee, Karen L. Reckamp, Huan Qiao, Ticiana A.B. Leal, Liping Du, Jennifer Hernandez, Vincent Huang, George R. Blumenschein et al. · 2019 · Journal of Thoracic Oncology
21. Is cancer biology different in older patients?
    Yannick Van Herck, Annelies Feyaerts, Shabbir M.H. Alibhai, Demetris Papamichael, Lore Decoster, Yentl Lambrechts, Michael Pinchuk, Oliver Edgar Bechter, Jaime Omar Herrera-Caceres, Frédéric Bibeau et al. · 2021 · The Lancet Healthy Longevity
22. Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification
    Kentaro Inamura · 2017 · International Journal of Molecular Sciences
23. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab
    Solange Peters, Keith M. Kerr, Rolf Arno Stahel · 2017 · Cancer Treatment Reviews
24. Emerging therapies for non-small cell lung cancer
    Chao Zhang, Natasha B. Leighl, Yi-Long Lung Cancer Wu, Wen‐Zhao Zhong · 2019 · Journal of Hematology & Oncology
25. Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
    Ibiayi Dagogo‐Jack, Marguerite M. Rooney, Jessica J. Lin, Rebecca J. Nagy, Beow Yong Yeap, Harper Hubbeling, Emily N. Chin, Jennifer Ackil, Anna F. Farago, Aaron N. Hata et al. · 2019 · Clinical Cancer Research
26. Personalized therapy for lung cancer: striking a moving target
    Suchita Pakkala, Suresh S. Ramalingam · 2018 · JCI Insight
27. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
    Kazuhiko Nakagawa, Toyoaki Hida, Hiroshi Nokihara, Masahiro Morise, Koichi Azuma, Young Hak Kim, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka et al. · 2019 · Lung Cancer
28. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
    Hiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu, Masahiro Morise, Haruko Daga, Yasushi Goto, Toshiyuki Kozuki, Satoru Miura, Takaaki Sasaki, Akihiro Tamiya et al. · 2019 · International Journal of Clinical Oncology
29. Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer
    Jose M. Pacheco, Dexiang Gao, Derek E. Smith, Thomas Purcell, Mark Jonathan Hancock, Paul A. Bunn, Tyler P. Robin, Arthur J. Liu, Sana D. Karam, Laurie E. Gaspar et al. · 2018 · Journal of Thoracic Oncology
30. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer
    Yujin Kudo, Cara Haymaker, J. Zhang, Alexandre Reuben, Dzifa Y. Duose, Junya Fujimoto, Sinchita Roy‐Chowdhuri, Luisa M. Solis Soto, Hitoshi Dejima, Edwin Roger Parra et al. · 2019 · Annals of Oncology
31. Role and targeting of anaplastic lymphoma kinase in cancer
    Carminia Maria Della Corte, Giuseppe Viscardi, Raimondo Di Liello, Morena Fasano, Erika Martinelli, Teresa Troiani, Fortunato Ciardiello, Floriana Morgillo · 2018 · Molecular Cancer
32. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK -Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study
    Benjamin Solomon, Todd Michael Bauer, Sai‐Hong Ignatius Ou, Geoffrey Liu, Hidetoshi Hayashi, Alessandra Bearz, Konstantin Penkov, Yi-Long Lung Cancer Wu, Oscar G. Arrieta, Jacek Jassem et al. · 2022 · Journal of Clinical Oncology
33. Oncogenic alterations in advanced NSCLC: a molecular super-highway
    Alex Friedlaender, Maurice Pérol, Giuseppe Luigi Banna, Kaushal Parikh, Alfredo Addeo · 2024 · Biomarker Research
34. Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance
    Zachary Schrank, Gagan Chhabra, Leo Y.-C. Lin, Tsatsral Iderzorig, Chike Osude, Nabiha Haleema Khan, Adijan Kuckovic, Sanjana Singh, Rachel J. Miller, Neelu Puri · 2018 · Cancers
35. Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
    Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Rizzo, Claudia Parisi, Alessandro Di Federico, Francesco Gelsomino, Andrea Ardizzoni · 2020 · Critical Reviews in Oncology/Hematology
36. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials
    D. Ross Camidge, Dong‐Wan Kim, Marcello Tiseo, Corey Jay Langer, Myung‐Ju Ahn, Alice Tsang Shaw, Rudolf Maria Huber, Maximilian Johannes Hochmair, Ki Hyeong Lee, Lyudmila A. Bazhenova et al. · 2018 · Journal of Clinical Oncology
37. Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
    Edouard Dantoing, Nicolas Piton, Mathieu Salaün, Luc Thiberville, Florian Guisier · 2021 · International Journal of Molecular Sciences
38. Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
    Vivek Subbiah, Justin F. Gainor, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Dwight Hall Owen, Byoung Chul Cho, Herbert Ho-Fung Loong, Caroline Elizabeth McCoach, Jared M. Weiss, Yu Jung Kim et al. · 2021 · Clinical Cancer Research
39. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
    Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang et al. · 2019 · The Lancet Respiratory Medicine
40. Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer
    Artem Kaznatcheev, Jeffrey S. Peacock, David Basanta, Andriy Marusyk, Jacob G. Scott · 2019 · Nature Ecology & Evolution
41. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
    John Victor Heymach, Lada Krilov, Anthony J. Alberg, Nancy Noel Baxter, Susan Marina Chang, Ryan Bruce Corcoran, William Dale, Angela M. DeMichele, Catherine Diefenbach, Robert Dreicer et al. · 2018 · Journal of Clinical Oncology
42. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer
    Joshua K. Sabari, Vamsidhar Velcheti, K. Shimizu, Matthew R. Strickland, Rebecca Suk Heist, Mohini Singh, Naema Nayyar, Anita Giobbie‐Hurder, Subba Rao Digumarthy, Justin F. Gainor et al. · 2022 · Clinical Cancer Research
43. Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression
    Daniele Tavernari, Elena Battistello, Elie Dheilly, Aaron S. Petruzzella, Marco Mina, Jessica Sordet‐Dessimoz, Solange Peters, Thorsten Krueger, David Gfeller, Nicolò Riggi et al. · 2021 · Cancer Discovery
44. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures
    Robert Vander Velde, Nara Yoon, Viktoriya Marusyk, Arda Durmaz, Andrew Dhawan, Daria Miroshnychenko, Diego Lozano‐Peral, Bina Desai, Olena V. Balynska, Jan Poleszczuk et al. · 2020 · Nature Communications
45. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
    Sebastian Yves Friedrich Michels, Bartomeu Massutí, Hans‐Ulrich Schildhaus, Jeremy G. Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohé, Delvys Rodríguez‐Abreu, Diana S.Y. Abdulla, Helge G. Bischoff et al. · 2019 · Journal of Thoracic Oncology
46. Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer
    Niamh Coleman, Lingzhi Hong, J. Zhang, John Victor Heymach, David S. Hong, Xiuning Le · 2021 · ESMO Open
47. Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
    Irene Moya‐Horno, Santiago Viteri, Niki Karachaliou, Rafael Rosell · 2018 · Therapeutic Advances in Medical Oncology
48. Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
    Maja Šutić, Ana Vukić, Jurica Baranašić, Asta Försti, Feđa Džubur, Miroslav Samaržija, Marko Jakopović, Luka Brčić, Jelena Knežević · 2021 · Journal of Personalized Medicine
49. The Evolving Modern Management of Brain Metastasis
    Peter Edward Fecci, Cosette D. Champion, Jacob P. Hoj, Courtney McKernan, Courtney Rory Goodwin, John P. Kirkpatrick, Carey K. Anders, Ann Marie Pendergast, John Howard Sampson · 2019 · Clinical Cancer Research
50. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Brain Metastases Working Group
    NU Lin, Tatiana Michelle Prowell, Antoinette R. Tan, Marina Kozak, Oliver Rosen, Laleh Amiri‐Kordestani, Julia R. White, Joohee Sul, Louise M. Perkins, K. Beal et al. · 2017 · Journal of Clinical Oncology
51. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
    Koutaroh Okada, Mitsugu Araki, Takuya Sakashita, Biao Ma, Ryo Kanada, Noriko Yanagitani, Atsushi Horiike, Sumie Koike, Tomoko Oh‐hara, Kana Watanabe et al. · 2019 · EBioMedicine
52. Roles of TGF-β Superfamily Proteins in Extravillous Trophoblast Invasion
    Yan Li, Junhao Yan, Hsun‐Ming Chang, Zi‐Jiang Chen, Peter C. K. Leung · 2021 · Trends in Endocrinology and Metabolism
53. Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
    Yuan Cheng, Tao Zhang, Qing Xu · 2021 · MedComm
54. Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey
    Jeffrey P. Gregg, Tianhong Li, Ken Y. Yoneda · 2019 · Translational Lung Cancer Research
55. Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer
    Mi Ran Yun, Dong Hwi Kim, Seok‐Young Kim, Hyeong-Seok Joo, You Won Lee, Hun Mi Choi, Chae Won Park, Seong Gu Heo, Han Na Kang, Sung Sook Lee et al. · 2020 · Clinical Cancer Research
56. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC
    Weihua Li, Lei Guo, Yutao Liu, Dong Lin, Lin Yang, Li Chen, Kaihua Liu, Yang Washington Shao, Jianming Ying · 2020 · Journal of Thoracic Oncology
57. Rare molecular subtypes of lung cancer
    Guilherme Harada, Soo‐Ryum Yang, Emiliano Cocco, Alexander Edward Dela Cruz Drilon · 2023 · Nature Reviews Clinical Oncology
58. Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis
    Conor Scott Gillespie, Mohammad A. Mustafa, George E. Richardson, Ali M. Alam, Keng Siang Lee, David Michael Hughes, Carles Escriu, Rasheed Zakaria · 2023 · Journal of Thoracic Oncology
59. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
    Todd Michael Bauer, Alice Tsang Shaw, Melissa Lynne Johnson, Alejandro Navarro, Justin F. Gainor, Holger C. Thurm, Yazdi K. Pithavala, Antonello Abbattista, Gerson Peltz, Enriqueta Felip · 2020 · Targeted Oncology
60. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
    Tatsuya Nagano, Motoko Yoshikawa TACHIHARA, Yoshihiro Nishimura · 2018 · Current Cancer Drug Targets
61. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
    Miguel García-Pardo, Maisam Makarem, Janice J.N. Li, Deirdre Kelly, Natasha B. Leighl · 2022 · British Journal of Cancer
62. Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
    Haiyang Guo, Jun Zhang, Chao Qin, Hang Yan, Tao Liu, Haiyang Hu, Shengjie Tang, Shoujun Tang, Haining Zhou · 2022 · Cells
63. The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
    Yue Pan, Chao Deng, Zhenhua Qiu, Chenghui Cao, Fang Wu · 2021 · Frontiers in Oncology
64. Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights
    Catherine Belle Meador, Aaron N. Hata · 2020 · Pharmacology & Therapeutics
65. Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
    Jingsi Dong, Bingjie Li, Dan Chi-Chia Lin, Qinghua Zhou, Depei Huang · 2019 · Frontiers in Pharmacology
66. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
    David König, Spasenija Savic Prince, Sacha I. Rothschild · 2021 · Cancers
67. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC
    Shannon S. Zhang, Misako Nagasaka, Viola Weijia Zhu, Sai‐Hong Ignatius Ou · 2021 · Lung Cancer
68. Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely
    Antonio Calles, Jonathan Wesley Riess, Julie Renee Brahmer · 2020 · American Society of Clinical Oncology Educational Book
69. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
    Enriqueta Felip, Alice Tsang Shaw, Alessandra Bearz, D. Ross Camidge, Benjamin Solomon, Jessica Ruth Bauman, Todd Michael Bauer, Solange Peters, Francesca Toffalorio, Antonello Abbattista et al. · 2021 · Annals of Oncology
70. Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer
    Julia K. Rotow, Philippe Gui, Wei Wu, Victoria M. Raymond, Richard Burnham Lanman, Frederic J. Kaye, Nir Peled, Ferran Fece de la Cruz, Brandon Nadres, Ryan Bruce Corcoran et al. · 2019 · Clinical Cancer Research
71. Inflammatory Myofibroblastic Tumour: State of the Art
    Louis Gros, Angelo Paolo Dei Tos, Robin L. Jones, Antonia Digklia · 2022 · Cancers
72. Characteristics and Outcome of ROS1-Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice
    Sehhoon Park, Beung‐Chul Ahn, Sung Won Lim, Jong‐Mu Sun, Hye Ryun Kim, Min Hee Hong, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Yoon‐La Choi et al. · 2018 · Journal of Thoracic Oncology
73. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
    Patrick R. Halliday, Collin Michael Blakely, Trever Grant Bivona · 2019 · Current Oncology Reports
74. Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer
    Kelly Cristina da Silva Oliveira, Iago Barroso Ramos, Jéssica Manoelli Costa da Silva, Williams Fernandes Barra, Gregory Joseph Riggins, Vikrant Palande, Catarina Torres Pinho, Milana Frenkel‐Morgenstern, Sidney Santos, Paulo Pimentel de Assumpção et al. · 2020 · Molecular Cancer Research
75. Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade
    César Serrano, Suzanne George · 2020 · Clinical Cancer Research
76. Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation
    Nicholas J. Thomas, Nathaniel James Myall, Fangdi Sun, Tejas Patil, Rao Rashid Mushtaq, Chandler Yu, Sumi Sinha, Erqi Liu Pollom, Seema Nagpal, D. Ross Camidge et al. · 2021 · Journal of Thoracic Oncology
77. Management of co-existent tuberculosis and lung cancer
    Jcm Ho, Chi‐Chiu Leung · 2018 · Lung Cancer
78. The prognostic significance of circulating tumor cells in head and neck and non‐small‐cell lung cancer
    Arutha Kulasinghe, Joanna Kapeleris, Rebecca Kimberley, Stephen R. Mattarollo, Erik W. Thompson, Jean Paul Thiery, Liz Kenny, Kenneth John O'Byrne, Chamindie Punyadeera · 2018 · Cancer Medicine
79. DrugMap: A quantitative pan-cancer analysis of cysteine ligandability
    Mariko Takahashi, Harrison Byron Chong, Siwen Zhang, Tzu-yi Yang, Matthew J. Lazarov, Stefan Andrew Harry, Michelle Maynard, Brendan J. Hilbert, Ryan D. White, Heather E. Murrey et al. · 2024 · Cell
80. Sex Differences in Lung Cancer
    Lauren May, Kathryn H. Shows, Patrick S. Nana-Sinkam, Howard Y. Li, Joseph W. Landry · 2023 · Cancers
81. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer
    Franziska Haderk, Yu‐Ting Chou, Lauren Čech, Celia Fernández-Méndez, Johnny X. Yu, Victor R. Olivas, Ismail Mustafa Meraz, Dora Barbosa Rabago, Daniel Lucas Kerr, Carlos F. Gómez et al. · 2024 · Nature Communications
82. KRAS Inhibitor Resistance in MET -Amplified KRAS G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms
    Suzuki, Shinichiro, Yonesaka, Kimio, Teramura, Takeshi, Takehara, Toshiyuki, Kato, Ryoji, Sakai, Hitomi, Haratani, Koji, Tanizaki, Junko, Kawakami, Hisato, Hayashi, Hidetoshi et al. · 2021 · Clinical Cancer Research
83. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
    Stanley I. Gutiontov, William Tyler Turchan, Liam Flinn Spurr, Sherin Juliet Rouhani, Carolina Soto Chervin, George Steinhardt, Angela M. Lager, Pankhuri Wanjari, Renuka Malik, Philip P. Connell et al. · 2021 · Scientific Reports
84. Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status
    Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Ryohei Katayama, Shigeki Nanjo, Azusa Tanimoto, Akihiro Nishiyama, Takayuki Nakagawa, Hirokazu Taniguchi, Takeshi Suzuki et al. · 2019 · Cancer Research
85. Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: An open‐label phase II trial
    Reiji Fukano, Tetsuya Mori, Masahiro Sekimizu, Ilseung Choi, Akiko Kada, Akiko Moriya Saito, Ryuta Asada, Kengo Takeuchi, Takashi Terauchi, Ukihide Tateishi et al. · 2020 · Cancer Science
86. Conquering lung cancer: current status and prospects for the future
    Robert Pirker · 2020 · Pulmonology
87. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion
    Matthias Preusser, Frank Winkler, Manuel Valiente, Christian Manegold, Elizabeth Cohen‐Jonathan Moyal, Georg Widhalm, Jörg‐Christian Tonn, Christoph Carl Zielinski · 2018 · ESMO Open
88. Tyrosine Kinase Receptors in Oncology
    Jorge Esteban-Villarrubia, J.J. Soto Castillo, Javier Pozas, María San Román, Inmaculada Orejana, Javier Torres-Jiménez, Alfredo Carrato, Teresa Alonso‐Gordoa, Javier Molina‐Cerrillo · 2020 · International Journal of Molecular Sciences
89. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm
    Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock · 2020 · Trends in cancer
90. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer
    Jason N. Rosenbaum, Ryan J. Bloom, Jason T. Forys, Jeffrey Hiken, Jon R. Armstrong, Julie Branson, Samantha N. McNulty, Priya Velu, Kymberlie Pepin, Haley Abel et al. · 2018 · Modern Pathology
91. Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
    Geeta G. Sharma, Inês Andrade Mota, Luca Mologni, Enrico Patrucco, Carlo B Gambacorti-Passerini, Roberto Chiarle · 2018 · Cancers
92. ABC transporters in breast cancer: their roles in multidrug resistance and beyond
    Anupama Modi, Dipayan Roy, Shailja Sharma, Jeewan Ram Vishnoi, Puneet Pareek, Poonam Abhay Elhence, Praveen Sharma, Purvi Purohit · 2022 · Journal of drug targeting
93. Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling
    Angel Qin, Adrienne Johnson, Jeffrey S. Ross, Vincent A. Miller, Siraj Mahamed Ali, Alexa Betzig Schrock, Shirish M. Gadgeel · 2018 · Journal of Thoracic Oncology
94. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
    Miriam Grazia Ferrara, Vincenzo Di Noia, Ettore D’Argento, Emanuele Vita, Paola Damiano, Antonella Cannella, Marta Ribelli, Sara Pilotto, Michèle Milella, Giampaolo Tortora et al. · 2020 · Cancers
95. Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
    Hayato Mizuta, Koutaroh Okada, Mitsugu Araki, Jun Adachi, Ai Takemoto, Justyna Kutkowska, Kohei Maruyama, Noriko Yanagitani, Tomoko Oh‐hara, Kana Watanabe et al. · 2021 · Nature Communications
96. Lung cancer in young adults aged 35 years or younger: A full-scale analysis and review
    Bailong Liu, Xiaoyue Quan, Changgen Xu, Jincai Lv, Cheng Li, Lihua Dong, Min Liu · 2019 · Journal of Cancer
97. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
    Edwards, A. Cole, Stalnecker, Clint A., Jean Morales, Alexis, Taylor, Khalilah E., Klomp, Jennifer E., Klomp, Jeffrey A., Waters, Andrew M., Sudhakar, Niranjan, Hallin, Jill, Tang, Tracy T. et al. · 2023 · Cancer Research
98. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors
    Assunta Sgambato, Francesca Casaluce, Paolo Maione, Cesare Gridelli · 2017 · Expert Review of Anticancer Therapy
99. PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice
    Iñaki Eguren‐Santamaría, Miguel F. Sanmamed, Sarah B. Goldberg, Harriet M. Kluger, Miguel Angel Idoate, Benjamin Y. Lu, Jesus Corral, Kurt Alex Schalper, Roy S. Herbst, Ignacio Gil Bazo · 2020 · Clinical Cancer Research
100. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma
     Sumanta Kumar Pal, Paulo Gustavo Bergerot, Nazlı Dizman, Cristiane Decat Bergerot, Jacob J. Adashek, Russell William Madison, Jon Chung, Siraj Mahamed Ali, Jeremy O. Jones, Ravi Salgia · 2018 · European Urology